All In Biotech

Investigational drug · Phase 3

VYD2311-MD

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for COVID-19.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "VYD2311-MD"

First trial start

2026

Jan 8, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VYD2311-MD", any sponsor or status.

Conditions studied

As listed on its trial records.

  • COVID-19

Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "VYD2311-MD" as an intervention, largest first.

All trials
  • Study of VYD2311 for the Prevention of COVID-19Pivotal-lookingActive, not recruiting

    Invivyd, Inc.Industry

    NCT07298434 · 1,770 participants (planned) · Start Jan 8, 2026 · Primary completion Aug 2026

    Drug: VYD2311-SD; VYD2311-MD and 1 more · For: COVID-19

    Sites: Long Beach, California; San Diego, California; Orlando, Florida · 20 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for COVID-19

  • BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)

  • VYD2311Phase 32 trials

    Invivyd, Inc. · Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine

  • DAS181Phase 31 trial

    Ansun Biopharma, Inc. · Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised

  • SCTA01Phase 31 trial

    Sinocelltech Ltd. · COVID-19, SARS-CoV-2

  • VYD222pemivibartPhase 31 trial

    Invivyd, Inc. · COVID-19, SARS-CoV-2

  • VYD2311-SDPhase 31 trial

    Invivyd, Inc. · COVID-19

  • CVXGACVXGA50, PIV5-SARS CoV-2Phase 22 trials

    CyanVac LLC · COVID-19

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.